[Problem] To provide a method for acquisition of data able to serve as an index for determining the likelihood that an ovarian endometriosis cyst is cancerous.

[Solution] This data acquisition method for determining the likelihood that an ovarian endometriosis cyst is cancerous includes an iron concentration measurement step for measuring the iron concentration in the cystic fluid of the ovarian endometriosis cyst. This diagnostic device for diagnosing the likelihood that an ovarian endometriosis cyst is cancerous is provided, at a minimum, with an iron concentration measurement unit for measuring the iron concentration in the cystic fluid of the ovarian endometriosis cyst.

Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.

The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.

The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.

[Problem] To provide a method for acquisition of data able to serve as an index for determining the likelihood that an ovarian endometriosis cyst is cancerous. Solution This data acquisition method for determining the likelihood that an ovarian endometriosis cyst is cancerous includes an iron concentration measurement step for measuring the iron concentration in the cystic fluid of the ovarian endometriosis cyst. This diagnostic device for diagnosing the likelihood that an ovarian endometriosis cyst is cancerous is provided, at a minimum, with an iron concentration measurement unit for measuring the iron concentration in the cystic fluid of the ovarian endometriosis cyst.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.

This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Mllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Mllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.

This application discloses methods of designing a treatment protocol for a human patient with ovarian cancer, as well as methods of treatment of ovarian cancer. This application also includes methods of characterizing an ovarian cancer in a human patient by the type of tumor.

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.